COSCIENS Net Income From Continuing Ops from 2010 to 2026
| CSCI Stock | 2.05 0.05 2.38% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -13.8 M | Current Value -13.1 M | Quarterly Volatility 6.2 M |
Check COSCIENS Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among COSCIENS Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Interest Expense of 99.3 K or Total Revenue of 16.6 M, as well as many indicators such as Price To Sales Ratio of 0.57, Dividend Yield of 0.0 or PTB Ratio of 0.59. COSCIENS financial statements analysis is a perfect complement when working with COSCIENS Biopharma Valuation or Volatility modules.
COSCIENS | Net Income From Continuing Ops | Build AI portfolio with COSCIENS Stock |
The Net Income From Continuing Ops trend for COSCIENS Biopharma offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether COSCIENS Biopharma is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest COSCIENS Biopharma's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of COSCIENS Biopharma over the last few years. It is COSCIENS Biopharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in COSCIENS Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
COSCIENS Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (1,386,021) | |
| Geometric Mean | 2,490,122 | |
| Coefficient Of Variation | (448.10) | |
| Mean Deviation | 4,719,672 | |
| Median | 1,455,582 | |
| Standard Deviation | 6,210,765 | |
| Sample Variance | 38.6T | |
| Range | 18.8M | |
| R-Value | (0.67) | |
| Mean Square Error | 22.6T | |
| R-Squared | 0.45 | |
| Significance | 0 | |
| Slope | (825,399) | |
| Total Sum of Squares | 617.2T |
COSCIENS Net Income From Continuing Ops History
About COSCIENS Biopharma Financial Statements
Investors use fundamental indicators, such as COSCIENS Biopharma's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although COSCIENS Biopharma's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Net Loss | -13.8 M | -13.1 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of COSCIENS Biopharma Correlation against competitors. For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is there potential for Biotechnology market expansion? Will COSCIENS introduce new products? Factors like these will boost the valuation of COSCIENS Biopharma. Projected growth potential of COSCIENS fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.54) | Revenue Per Share | Quarterly Revenue Growth 0.176 | Return On Assets | Return On Equity |
Understanding COSCIENS Biopharma requires distinguishing between market price and book value, where the latter reflects COSCIENS's accounting equity. The concept of intrinsic value - what COSCIENS Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push COSCIENS Biopharma's price substantially above or below its fundamental value.
It's important to distinguish between COSCIENS Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding COSCIENS Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, COSCIENS Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.